Adar Poonawalla-led Serum Institute of India is in advanced talks with Trivitron Healthcare to scale up its investment in MyLab Discovery Solutions and expand the Pune-based diagnostics company internationally through a new joint venture.
Glimpse:
The collaboration involves creating MyLab Trivitron Next Gen Technologies as part of a restructuring effort to clean up liabilities and build a stronger platform for growth. MyLab, founded in 2016, rose to prominence during the COVID-19 pandemic by developing India’s first indigenous RT-PCR test kits. The move leverages Trivitron’s extensive global distribution network and manufacturing expertise to help MyLab’s high end molecular diagnostics reach international markets. A formal agreement is expected in the coming days following due diligence.
Adar Poonawalla’s Serum Institute of India is close to finalizing an important partnership with Chennai based Trivitron Healthcare to significantly boost its stake in MyLab Discovery Solutions and drive the company’s expansion beyond Indian borders. The two parties have set up a new joint venture named MyLab Trivitron Next Gen Technologies as part of a strategic restructuring that separates existing liabilities and prepares a cleaner entity for fresh investments and international growth. This development comes as Serum Institute looks to diversify its portfolio beyond vaccines into the broader diagnostics and digital health space.
MyLab Discovery Solutions, established in 2016 in Pune, gained widespread recognition during the COVID-19 outbreak for introducing India’s first locally developed RT-PCR testing kits. The company has since focused on advanced molecular diagnostics technologies aimed at early detection and monitoring of various health conditions. With Serum Institute already holding a substantial stake in MyLab including additional exposure through promoter linked entities the proposed alliance seeks to combine MyLab’s innovation strengths with Trivitron’s proven global footprint spanning the US, Europe, and Asia, along with its capabilities in medical devices and in-vitro diagnostics.
The joint venture is designed to enhance manufacturing scale, distribution reach, and market access for MyLab’s high end diagnostic solutions. Trivitron brings operational expertise and an established international presence that can accelerate MyLab’s entry into overseas markets. Discussions between the parties have progressed actively over the past couple of months, with the transaction now in the advanced stage of due diligence. While specific financial terms remain undisclosed, sources indicate that a final agreement could be signed shortly.
This partnership reflects a growing trend among Indian healthcare players to strengthen their position in the global diagnostics arena by forming complementary alliances. It positions MyLab to compete more effectively on the world stage by merging cutting edge diagnostic innovation with robust production and supply chain infrastructure.
“We are structuring the JV with Trivitron for better international opportunities in distribution and manufacturing with their global reach and presence, with a focus on high-end technologies of MyLab”
By
HB Team
Related News
